Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis

Colin Klein, Tatiana Prokhorov, Alla Miniovich, Eugenia Dobronevsky, Jose M. Rabey*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


OBJECTIVES: To evaluate the long-term outcome of quetiapine (QTP) use for drug-induced psychosis in Parkinson disease as assessed by the primary caregiver using the Clinical Global Impression Scale. METHODS: Thirty-five patients (mean age ± SD, 76.1 ± 5.9 years; mean disease duration ± SD, 10.3 ± 5.3 years; 19 with dementia) were followed up over a 24-month period. RESULTS: At 6 months, 20 (57%) responded to QTP, of whom 11 (31%) maintained their improvement in the long term (for 24 months). Altogether, 15 patients (43%) responded to QTP in the long term (11 were still on treatment at 24 months, 3 stopped because of improvement and medication was no longer required, and 3 stopped because of financial reasons [one was responding positively by the time of stopping medication]). The medications of nonresponding patients (n = 15) were switched to clozapine, with a positive response in 12 patients (80%). CONCLUSIONS: In long-term follow-up, 31% of parkinsonian patients with psychosis treated with QTP were still on QTP therapy at 24 months. For those failing to respond to QTP, clozapine was an effective alternative therapy.

Original languageEnglish
Pages (from-to)215-219
Number of pages5
JournalClinical Neuropharmacology
Issue number4
StatePublished - Jul 2006


  • Atypical antipsychotics
  • Psychosis and Parkinson disease
  • Quetiapine


Dive into the research topics of 'Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis'. Together they form a unique fingerprint.

Cite this